2021
Left atrial evaluation by cardiovascular magnetic resonance: sensitive and unique biomarkers
Peters DC, Lamy J, Sinusas AJ, Baldassarre LA. Left atrial evaluation by cardiovascular magnetic resonance: sensitive and unique biomarkers. European Heart Journal - Cardiovascular Imaging 2021, 23: 14-30. PMID: 34718484, PMCID: PMC8685602, DOI: 10.1093/ehjci/jeab221.Peer-Reviewed Original ResearchConceptsLate gadolinium enhancementAtrial fibrillationCardiovascular magnetic resonanceDiastolic dysfunctionEjection fractionAF recurrenceAtrial fibrosisNew-onset atrial fibrillationPost-operative atrial fibrillationLongitudinal LA strainExtent of fibrosisLong-axis cine imagesCine imagesAtrial imagingCardiovascular eventsLA volumeRisk stratificationAF subjectsPrognostic informationHypertrophic cardiomyopathyLA strainGadolinium enhancementSensitive markerAblation proceduresMagnetic resonanceAdverse cardiovascular events in patients treated with mogamulizumab
Kwan J, Henry M, Cook K, Higgins A, Cuomo J, Foss F, Baldassarre L. Adverse cardiovascular events in patients treated with mogamulizumab. American Heart Journal Plus Cardiology Research And Practice 2021, 9: 100049. PMID: 38559371, PMCID: PMC10978139, DOI: 10.1016/j.ahjo.2021.100049.Peer-Reviewed Original ResearchAdverse cardiovascular eventsMogamulizumab therapyCardiovascular eventsHeart failureAdverse outcomesNon-cardiovascular eventsWorld Health Organization databaseFatal adverse outcomesT-cell leukemiaACE occurrenceMogamulizumab treatmentNew hypertensionAdverse eventsCardiac deathVentricular arrhythmiasFatal outcomeUnique patientsCardiovascular toxicityMyocardial infarctionImportant treatmentHigh mortalityPatientsMogamulizumabTherapyOrganization database
2020
Opportunities for improved cardiovascular disease prevention in oncology patients.
Bravo-Jaimes K, Marcellon R, Varanitskaya L, Kim PY, Iliescu C, Gilchrist SC, Baldassarre LA, Manisty C, Ghosh AK, Guha A, Lopez-Mattei JC. Opportunities for improved cardiovascular disease prevention in oncology patients. Current Opinion In Cardiology 2020, 35: 531-537. PMID: 32649353, DOI: 10.1097/hco.0000000000000767.Peer-Reviewed Original ResearchConceptsCardiovascular disease preventionCancer patientsDisease preventionCardiovascular disease prevention guidelinesCardiac risk factor modificationCancer treatmentCardiometabolic disease managementDisease prevention guidelinesCardiovascular risk factorsHigh cardiovascular riskRisk factor modificationAdverse cardiovascular outcomesRisk of cardiotoxicityOngoing clinical trialsNonpharmacologic therapiesCardiovascular eventsCardiovascular outcomesCardiovascular riskOncology patientsCancer survivorsPrevention guidelinesAdverse outcomesFactor modificationCardiorespiratory fitnessRisk factors